Bildnachweis: Noctrix Health.
Angelini Ventures, the corporate venture arm of Angelini Industries focused on Biotech and Healthtech investments, has announced the acquisition of its portfolio company Noctrix Health by ResMed (NYSE: RMD), a global provider of sleep health and respiratory care solutions. The transaction is valued at 340 million USD.
The deal represents a significant milestone for Angelini Ventures and underscores its strategy of backing differentiated healthcare technologies addressing substantial unmet medical needs. Through the planned integration of Noctrix Health’s technology into ResMed’s broader sleep health ecosystem, the acquisition is expected to support expanded patient access and enhance care delivery. Founded in 2016, Noctrix Health develops wearable, clinically validated neuromodulation therapies for chronic neurological and sleep-related conditions. The company’s lead product, Nidra, is the first FDA-authorised non-invasive therapy for moderate-to-severe Restless Legs Syndrome (RLS), providing a novel treatment option for millions of patients worldwide. Tanja Dowe, Managing Director at Angelini Ventures and Board Observer at Noctrix Health prior to the acquisition, said: “It has been a privilege to partner with the Noctrix team during such a pivotal phase of the company’s growth. The speed and quality of execution across clinical development, regulatory approval and commercialization have been exceptional. We are proud to have supported the company as it advanced a first-in-class therapy for patients with Restless Legs Syndrome.”
Investment in 2024
Angelini Ventures invested in Noctrix Health in 2024 as part of the company’s $40 million Series C financing round, alongside a syndicate of leading healthcare investors. The financing supported the company’s continued clinical development and commercial expansion. “This marks our first successful exit, reaffirming our strategy of backing disruptive healthcare companies with the potential to address significant unmet medical needs,” said Paolo Di Giorgio, CEO and Managing Director of Angelini Ventures. “Noctrix Health exemplifies the type of company we seek to support – combining cutting-edge science, technological innovation and clear clinical relevance. We are delighted to see that the company’s technology will become integrated into ResMed’s broader connected health ecosystem, creating new opportunities to expand patient access and impact at scale.”
Commenting on the transaction, Sergio Marullo di Condojanni, CEO of Angelini Industries, said: “This milestone further reflects Angelini Industries’ commitment to support scientific and technological innovation capable of generating meaningful impact for patients and healthcare systems worldwide. Noctrix represents a compelling example of how breakthrough healthcare innovation can evolve into scalable solutions with global relevance.”
The acquisition marks Angelini Ventures’ first exit and further highlights the firm’s approach of combining capital, strategic expertise, operational capabilities and a global network of founders, investors and academic partners to support the next generation of healthcare innovators.
